{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T21:55:20Z","timestamp":1790286920871,"version":"4.1.0"},"reference-count":126,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","theclinics.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Dermatologic Clinics"],"published-print":{"date-parts":[[2024,7]]},"DOI":"10.1016\/j.det.2024.02.012","type":"journal-article","created":{"date-parts":[[2024,3,15]],"date-time":"2024-03-15T14:06:54Z","timestamp":1710511614000},"page":"481-493","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"title":["Immune Checkpoint Inhibitor-Induced Psoriasis"],"prefix":"10.1016","volume":"42","author":[{"given":"Jolanta J.","family":"Pach","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nina","family":"Mbonu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shaman","family":"Bhullar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey M.","family":"Cohen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan S.","family":"Leventhal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.det.2024.02.012_bib1","first-page":"123","article-title":"Cutaneous Toxicities of Immune Checkpoint Inhibitors: The Role of the Dermatologist","volume":"93","author":"Tattersall","year":"2020","journal-title":"Yale J Biol Med"},{"issue":"Suppl 1","key":"10.1016\/j.det.2024.02.012_bib2","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1007\/s40257-018-0384-3","article-title":"Toxic Side Effects of Targeted Therapies and Immunotherapies Affecting the Skin, Oral Mucosa, Hair, and Nails","volume":"19","author":"Lacouture","year":"2018","journal-title":"Am J Clin Dermatol"},{"issue":"5","key":"10.1016\/j.det.2024.02.012_bib3","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1016\/j.jaad.2020.03.132","article-title":"Immune checkpoint inhibitor-related dermatologic adverse events","volume":"83","author":"Geisler","year":"2020","journal-title":"J\u00a0Am Acad Dermatol"},{"issue":"5","key":"10.1016\/j.det.2024.02.012_bib4","doi-asserted-by":"crossref","first-page":"1156","DOI":"10.1016\/j.jaad.2022.11.051","article-title":"The spectrum of cutaneous immune-related adverse events in patients with skin of color","volume":"88","author":"Belzer","year":"2023","journal-title":"J\u00a0Am Acad Dermatol"},{"issue":"2","key":"10.1016\/j.det.2024.02.012_bib5","doi-asserted-by":"crossref","first-page":"e14830","DOI":"10.1111\/dth.14830","article-title":"Psoriasis and psoriasiform reactions secondary to immune checkpoint inhibitors","volume":"34","author":"Cutroneo","year":"2021","journal-title":"Dermatol Ther"},{"issue":"8","key":"10.1016\/j.det.2024.02.012_bib6","doi-asserted-by":"crossref","first-page":"940","DOI":"10.1001\/jamadermatol.2021.2007","article-title":"Psoriasis Prevalence in Adults in the United States","volume":"157","author":"Armstrong","year":"2021","journal-title":"JAMA Dermatol"},{"issue":"5","key":"10.1016\/j.det.2024.02.012_bib7","doi-asserted-by":"crossref","first-page":"1310","DOI":"10.1016\/j.jaad.2020.08.137","article-title":"Immune checkpoint-mediated psoriasis: A multicenter European study of 115 patients from the European Network for Cutaneous Adverse Event to Oncologic Drugs (ENCADO) group","volume":"84","author":"Nikolaou","year":"2021","journal-title":"J\u00a0Am Acad Dermatol"},{"issue":"1","key":"10.1016\/j.det.2024.02.012_bib8","doi-asserted-by":"crossref","first-page":"ltac016","DOI":"10.1093\/immadv\/ltac016","article-title":"Prevalence of inverse psoriasis subtype with immune checkpoint inhibitors","volume":"2","author":"Jfri","year":"2022","journal-title":"Immunother Adv"},{"issue":"2","key":"10.1016\/j.det.2024.02.012_bib9","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1016\/j.jaad.2022.02.030","article-title":"Treatment of immune checkpoint inhibitor-mediated psoriasis: A systematic review","volume":"87","author":"Said","year":"2022","journal-title":"J\u00a0Am Acad Dermatol"},{"issue":"10","key":"10.1016\/j.det.2024.02.012_bib10","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2021-003066","article-title":"Immune checkpoint inhibitors in patients with pre-existing psoriasis: safety and efficacy","volume":"9","author":"Halle","year":"2021","journal-title":"J Immunother Cancer"},{"issue":"4","key":"10.1016\/j.det.2024.02.012_bib11","doi-asserted-by":"crossref","first-page":"990","DOI":"10.1016\/j.jaad.2018.10.062","article-title":"Inflammatory eruptions associated with immune checkpoint inhibitor therapy: A single-institution retrospective analysis with stratification of reactions by toxicity and implications for management","volume":"80","author":"Coleman","year":"2019","journal-title":"J\u00a0Am Acad Dermatol"},{"issue":"4","key":"10.1016\/j.det.2024.02.012_bib12","doi-asserted-by":"crossref","first-page":"956","DOI":"10.1016\/j.jaad.2020.09.054","article-title":"Cutaneous adverse events caused by immune checkpoint inhibitors","volume":"85","author":"Quach","year":"2021","journal-title":"J\u00a0Am Acad Dermatol"},{"issue":"5","key":"10.1016\/j.det.2024.02.012_bib13","doi-asserted-by":"crossref","first-page":"1198","DOI":"10.1016\/j.jaad.2023.01.002","article-title":"The effect of baseline eczema or psoriasis on the morphology of cutaneous immune-related adverse events due to immune checkpoint inhibitor therapy","volume":"88","author":"Belzer","year":"2023","journal-title":"J Am Acad Dermatol"},{"issue":"5","key":"10.1016\/j.det.2024.02.012_bib14","doi-asserted-by":"crossref","first-page":"e254","DOI":"10.1111\/jdv.14011","article-title":"Anti-PD1-induced psoriasis: a study of 21 patients","volume":"31","author":"Bonigen","year":"2017","journal-title":"J\u00a0Eur Acad Dermatol Venereol"},{"issue":"12","key":"10.1016\/j.det.2024.02.012_bib15","doi-asserted-by":"crossref","first-page":"2100","DOI":"10.1002\/art.41068","article-title":"Safety and Efficacy of Immune Checkpoint Inhibitors in Patients With Cancer and Preexisting Autoimmune Disease: A Nationwide, Multicenter Cohort Study","volume":"71","author":"Tison","year":"2019","journal-title":"Arthritis Rheumatol"},{"issue":"6","key":"10.1016\/j.det.2024.02.012_bib16","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1158\/2326-6066.CIR-18-0682","article-title":"IL17A Blockade Successfully Treated Psoriasiform Dermatologic Toxicity from Immunotherapy","volume":"7","author":"Johnson","year":"2019","journal-title":"Cancer Immunol Res"},{"issue":"10","key":"10.1016\/j.det.2024.02.012_bib17","first-page":"e5824","article-title":"A\u00a0Novel Approach to the Treatment of Pembrolizumab-induced Psoriasis Exacerbation: A Case Report","volume":"11","author":"Monsour","year":"2019","journal-title":"Cureus"},{"issue":"3","key":"10.1016\/j.det.2024.02.012_bib18","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1097\/DER.0000000000000776","article-title":"Systemic Treatment of Cutaneous Adverse Events After Immune Checkpoint Inhibitor Therapy: A Review","volume":"34","author":"Brown","year":"2023","journal-title":"Dermatitis"},{"key":"10.1016\/j.det.2024.02.012_bib19","doi-asserted-by":"crossref","first-page":"16082","DOI":"10.1038\/nrdp.2016.82","volume":"2","author":"Greb","year":"2016","journal-title":"Psoriasis. Nat Rev Dis Primers."},{"issue":"2","key":"10.1016\/j.det.2024.02.012_bib20","first-page":"169","article-title":"PD-1 blockade augments Th1 and Th17 and suppresses Th2 responses in peripheral blood from patients with prostate and advanced melanoma cancer","volume":"35","author":"Dulos","year":"2012","journal-title":"J\u00a0Immunother"},{"key":"10.1016\/j.det.2024.02.012_bib21","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/j.ejca.2019.01.010","article-title":"Successful treatment of psoriasis induced by immune checkpoint inhibitors with apremilast","volume":"110","author":"Fattore","year":"2019","journal-title":"Eur J Cancer"},{"issue":"5","key":"10.1016\/j.det.2024.02.012_bib22","doi-asserted-by":"crossref","first-page":"1182","DOI":"10.1016\/j.jaad.2022.12.019","article-title":"Risk of rebound psoriasis flare from systemic corticosteroid use in patients with psoriasis: A retrospective cohort study","volume":"88","author":"Kresch","year":"2023","journal-title":"J\u00a0Am Acad Dermatol"},{"issue":"2","key":"10.1016\/j.det.2024.02.012_bib23","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1159\/000491572","article-title":"Psoriasis Vulgaris Exacerbation during Treatment with a PD-1 Checkpoint Inhibitor: Case Report and Literature Review","volume":"10","author":"De Bock","year":"2018","journal-title":"Case Rep Dermatol"},{"issue":"30","key":"10.1016\/j.det.2024.02.012_bib24","doi-asserted-by":"crossref","first-page":"2746","DOI":"10.1200\/JCO.18.02141","article-title":"Treatment Outcomes of Immune-Related Cutaneous Adverse Events","volume":"37","author":"Phillips","year":"2019","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.det.2024.02.012_bib25","unstructured":"Common Terminology Criteria for Adverse Events (CTCAE), v5. Available at: ctep.cancer.gov, 2018."},{"issue":"3","key":"10.1016\/j.det.2024.02.012_bib26","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1016\/j.jaad.2022.06.1186","article-title":"Impact of biologic therapy on cancer outcomes in patients with immune checkpoint inhibitor-induced bullous pemphigoid","volume":"88","author":"Said","year":"2023","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.det.2024.02.012_bib27","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1016\/j.lungcan.2017.04.007","article-title":"Development of psoriatic arthritis during nivolumab therapy for metastatic non-small cell lung cancer, clinical outcome analysis and review of the literature","volume":"108","author":"Ruiz-Banobre","year":"2017","journal-title":"Lung Cancer"},{"issue":"28","key":"10.1016\/j.det.2024.02.012_bib28","doi-asserted-by":"crossref","first-page":"2872","DOI":"10.1200\/JCO.2018.79.0006","article-title":"Impact of Baseline Steroids on Efficacy of Programmed Cell Death-1 and Programmed Death-Ligand 1 Blockade in Patients With Non-Small-Cell Lung Cancer","volume":"36","author":"Arbour","year":"2018","journal-title":"J\u00a0Clin Oncol"},{"issue":"18","key":"10.1016\/j.det.2024.02.012_bib29","doi-asserted-by":"crossref","first-page":"3706","DOI":"10.1002\/cncr.31629","article-title":"High-dose glucocorticoids for the treatment of ipilimumab-induced hypophysitis is associated with reduced survival in patients with melanoma","volume":"124","author":"Faje","year":"2018","journal-title":"Cancer"},{"issue":"4","key":"10.1016\/j.det.2024.02.012_bib30","doi-asserted-by":"crossref","first-page":"300","DOI":"10.5826\/dpc.0904a11","article-title":"Psoriasis in Patients With Active Lung Cancer: Is Apremilast a Safe Option?","volume":"9","author":"Apalla","year":"2019","journal-title":"Dermatol Pract Concept"},{"issue":"2","key":"10.1016\/j.det.2024.02.012_bib31","doi-asserted-by":"crossref","first-page":"259","DOI":"10.2340\/00015555-2212","article-title":"Exacerbation of Psoriasis During Nivolumab Therapy for Metastatic Melanoma","volume":"96","author":"Matsumura","year":"2016","journal-title":"Acta Derm Venereol"},{"issue":"12","key":"10.1016\/j.det.2024.02.012_bib32","doi-asserted-by":"crossref","first-page":"2277","DOI":"10.1111\/jdv.13354","article-title":"European S3-Guidelines on the systemic treatment of psoriasis vulgaris--Update 2015--Short version--EDF in cooperation with EADV and IPC","volume":"29","author":"Nast","year":"2015","journal-title":"J\u00a0Eur Acad Dermatol Venereol"},{"issue":"11","key":"10.1016\/j.det.2024.02.012_bib33","doi-asserted-by":"crossref","first-page":"1322","DOI":"10.1111\/1346-8138.15541","article-title":"Systemic capillary leak syndrome triggered by anti-programmed death 1 checkpoint inhibitor in psoriasis","volume":"47","author":"Umeda","year":"2020","journal-title":"J\u00a0Dermatol"},{"key":"10.1016\/j.det.2024.02.012_bib34","article-title":"A\u00a0case report of psoriasis flare following immunotherapy: Report of an important entity and literature review","volume":"8","author":"Politi","year":"2020","journal-title":"SAGE Open Med Case Rep"},{"issue":"4","key":"10.1016\/j.det.2024.02.012_bib35","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.1158\/1078-0432.CCR-20-3449","article-title":"Combining Nivolumab and Ipilimumab with Infliximab or Certolizumab in Patients with Advanced Melanoma: First Results of a Phase Ib Clinical Trial","volume":"27","author":"Montfort","year":"2021","journal-title":"Clin Cancer Res"},{"issue":"5","key":"10.1016\/j.det.2024.02.012_bib36","first-page":"175","article-title":"Incidence and Clinical Impact of Anti-TNFalpha Treatment of Severe Immune Checkpoint Inhibitor-induced Colitis in Advanced Melanoma: The Mecolit Survey","volume":"42","author":"Lesage","year":"2019","journal-title":"J\u00a0Immunother"},{"issue":"1","key":"10.1016\/j.det.2024.02.012_bib37","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1186\/s40425-019-0711-0","article-title":"Concurrent therapy with immune checkpoint inhibitors and TNFalpha blockade in patients with gastrointestinal immune-related adverse events","volume":"7","author":"Badran","year":"2019","journal-title":"J\u00a0Immunother Cancer"},{"issue":"1","key":"10.1016\/j.det.2024.02.012_bib38","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1016\/j.jaad.2020.08.050","article-title":"Low gene expression of TNF, IL17A, IL23A, and IL12B in tumors: A safety surrogate to predict cancer survival associated with biologic therapies","volume":"85","author":"Klebanov","year":"2021","journal-title":"J\u00a0Am Acad Dermatol"},{"issue":"2","key":"10.1016\/j.det.2024.02.012_bib39","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1007\/s00520-021-06548-4","article-title":"Biologic therapies for checkpoint inhibitor-induced cutaneous toxicities: a single-institution study of 17 consecutively treated patients","volume":"30","author":"Lo","year":"2022","journal-title":"Support Care Cancer"},{"issue":"20","key":"10.1016\/j.det.2024.02.012_bib40","doi-asserted-by":"crossref","first-page":"1989","DOI":"10.1056\/NEJMc1703047","article-title":"Reversal of Autoimmune Toxicity and Loss of Tumor Response by Interleukin-17 Blockade","volume":"376","author":"Esfahani","year":"2017","journal-title":"N\u00a0Engl J Med"},{"issue":"4","key":"10.1016\/j.det.2024.02.012_bib41","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1684\/ejd.2021.4087","article-title":"Ixekizumab for the treatment of erythrodermic psoriasis triggered by durvalumab-tremelimumab in a cancer patient","volume":"31","author":"Vinaixa Aranzazu","year":"2021","journal-title":"Eur J Dermatol"},{"issue":"5","key":"10.1016\/j.det.2024.02.012_bib42","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1111\/cup.14185","article-title":"Severe de novo pustular psoriasiform immune-related adverse event associated with nivolumab treatment for metastatic esophageal adenocarcinoma","volume":"49","author":"Seervai","year":"2022","journal-title":"J\u00a0Cutan Pathol"},{"key":"10.1016\/j.det.2024.02.012_bib43","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/j.jdcr.2021.03.029","article-title":"Nivolumab-induced psoriasis successfully treated with risankizumab-rzaa in a patient with stage III melanoma","volume":"11","author":"Glinos","year":"2021","journal-title":"JAAD Case Rep"},{"issue":"12","key":"10.1016\/j.det.2024.02.012_bib44","doi-asserted-by":"crossref","first-page":"e464","DOI":"10.1111\/1346-8138.15091","article-title":"Histologically-diagnosed psoriasiform dermatitis induced by nivolumab successfully controlled by etanercept: A case report","volume":"46","author":"Kim","year":"2019","journal-title":"J\u00a0Dermatol"},{"issue":"11","key":"10.1016\/j.det.2024.02.012_bib45","doi-asserted-by":"crossref","first-page":"2087","DOI":"10.1093\/rheumatology\/kew281","article-title":"Psoriasis and psoriatic arthritis induced by nivolumab in a patient with advanced lung cancer","volume":"55","author":"Law-Ping-Man","year":"2016","journal-title":"Rheumatology (Oxford)"},{"issue":"6","key":"10.1016\/j.det.2024.02.012_bib46","doi-asserted-by":"crossref","first-page":"1322","DOI":"10.1158\/0008-5472.CAN-16-2324","article-title":"Immune Toxicities Elicted by CTLA-4 Blockade in Cancer Patients Are Associated with Early Diversification of the T-cell Repertoire","volume":"77","author":"Oh","year":"2017","journal-title":"Cancer Res"},{"issue":"3","key":"10.1016\/j.det.2024.02.012_bib47","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1093\/annonc\/mdw640","article-title":"Antibody-mediated thyroid dysfunction during T-cell checkpoint blockade in patients with non-small-cell lung cancer","volume":"28","author":"Osorio","year":"2017","journal-title":"Ann Oncol"},{"issue":"7","key":"10.1016\/j.det.2024.02.012_bib48","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1200\/JCO.2014.57.4756","article-title":"Vitiligo-like depigmentation in patients with stage III-IV melanoma receiving immunotherapy and its association with survival: a systematic review and meta-analysis","volume":"33","author":"Teulings","year":"2015","journal-title":"J\u00a0Clin Oncol"},{"issue":"2","key":"10.1016\/j.det.2024.02.012_bib49","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1001\/jamadermatol.2021.5476","article-title":"Association of Cutaneous Immune-Related Adverse Events With Increased Survival in Patients Treated With Anti-Programmed Cell Death 1 and Anti-Programmed Cell Death Ligand 1 Therapy","volume":"158","author":"Tang","year":"2022","journal-title":"JAMA Dermatol"},{"issue":"6","key":"10.1016\/j.det.2024.02.012_bib50","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.1016\/j.jaad.2018.05.035","article-title":"Characterization of dermatitis after PD-1\/PD-L1 inhibitor therapy and association with multiple oncologic outcomes: A retrospective case-control study","volume":"79","author":"Min Lee","year":"2018","journal-title":"J\u00a0Am Acad Dermatol"},{"issue":"2","key":"10.1016\/j.det.2024.02.012_bib51","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1016\/j.jaad.2019.06.035","article-title":"Survival and prognosis of individuals receiving programmed cell death 1 inhibitor with and without immunologic cutaneous adverse events","volume":"82","author":"Chan","year":"2020","journal-title":"J\u00a0Am Acad Dermatol"},{"issue":"2","key":"10.1016\/j.det.2024.02.012_bib52","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1056\/NEJMra1703481","article-title":"Immune-Related Adverse Events Associated with Immune Checkpoint Blockade","volume":"378","author":"Postow","year":"2018","journal-title":"N\u00a0Engl J Med"},{"issue":"6","key":"10.1016\/j.det.2024.02.012_bib53","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1016\/j.currproblcancer.2017.10.003","article-title":"Anti-PD1\/PDL1 induced psoriasis","volume":"41","author":"Voudouri","year":"2017","journal-title":"Curr Probl Cancer"},{"issue":"10","key":"10.1016\/j.det.2024.02.012_bib54","doi-asserted-by":"crossref","first-page":"e89","DOI":"10.1111\/jdv.13336","article-title":"Exacerbation of psoriasis vulgaris during nivolumab for oral mucosal melanoma","volume":"30","author":"Kato","year":"2016","journal-title":"J\u00a0Eur Acad Dermatol Venereol"},{"issue":"7","key":"10.1016\/j.det.2024.02.012_bib55","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1001\/jamadermatol.2015.0249","article-title":"Occurrence of Psoriasiform Eruption During Nivolumab Therapy for Primary Oral Mucosal Melanoma","volume":"151","author":"Ohtsuka","year":"2015","journal-title":"JAMA Dermatol"},{"issue":"3","key":"10.1016\/j.det.2024.02.012_bib56","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1016\/j.ad.2015.07.012","article-title":"a new Drug That Can Induce Exacerbations of Psoriasis","volume":"107","author":"Sahuquillo-Torralba","year":"2016","journal-title":"Actas Dermosifiliogr"},{"issue":"3","key":"10.1016\/j.det.2024.02.012_bib57","doi-asserted-by":"crossref","first-page":"e55","DOI":"10.1111\/1346-8138.14167","article-title":"New onset of psoriasis during nivolumab treatment for lung cancer","volume":"45","author":"Chujo","year":"2018","journal-title":"J\u00a0Dermatol"},{"issue":"1","key":"10.1016\/j.det.2024.02.012_bib58","first-page":"256","article-title":"Development of de novo psoriasis during nivolumab therapy in a patient with small cell lung cancer","volume":"26","author":"D","year":"2020","journal-title":"J\u00a0Oncol Pharm Pract"},{"issue":"2","key":"10.1016\/j.det.2024.02.012_bib59","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1684\/ejd.2020.3723","article-title":"Pembrolizumab-induced psoriasis vulgaris successfully treated with apremilast","volume":"30","author":"Takama","year":"2020","journal-title":"Eur J Dermatol"},{"key":"10.1016\/j.det.2024.02.012_bib60","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/j.ejca.2018.11.025","article-title":"Dramatic response of nivolumab-associated psoriasiform dermatitis to etoposide","volume":"107","author":"Rios","year":"2019","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.det.2024.02.012_bib61","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1016\/j.jdcr.2021.03.015","article-title":"Apremilast for immune checkpoint inhibitor-induced psoriasis: A case series","volume":"11","author":"Mayor Ibarguren","year":"2021","journal-title":"JAAD Case Rep"},{"issue":"5","key":"10.1016\/j.det.2024.02.012_bib62","doi-asserted-by":"crossref","first-page":"2005","DOI":"10.1111\/jocd.14889","article-title":"Atezolizumab induced de novo rupoid psoriasis: A rare cutaneous manifestation of immune checkpoint inhibitors","volume":"21","author":"Mohta","year":"2022","journal-title":"J\u00a0Cosmet Dermatol"},{"issue":"11","key":"10.1016\/j.det.2024.02.012_bib63","doi-asserted-by":"crossref","first-page":"e570","DOI":"10.1111\/1346-8138.16144","article-title":"Occurrence of palmoplantar pustulosis during atezolizumab therapy for non-small cell lung cancer","volume":"48","author":"Onishi","year":"2021","journal-title":"J\u00a0Dermatol"},{"issue":"9","key":"10.1016\/j.det.2024.02.012_bib64","doi-asserted-by":"crossref","first-page":"916","DOI":"10.1111\/1346-8138.16427","article-title":"Loss of epidermal Langerhans cells in psoriasiform lesions of de novo induced or worsened pre-existing psoriasis following uses of immune checkpoint inhibitors","volume":"49","author":"Kase","year":"2022","journal-title":"J\u00a0Dermatol"},{"issue":"11","key":"10.1016\/j.det.2024.02.012_bib65","doi-asserted-by":"crossref","first-page":"1135","DOI":"10.1002\/kjm2.12595","article-title":"A\u00a0case of de novo psoriasis secondary to atezolizumab in a patient with hepatocellular carcinoma","volume":"38","author":"Lim","year":"2022","journal-title":"Kaohsiung J Med Sci"},{"issue":"5","key":"10.1016\/j.det.2024.02.012_bib66","doi-asserted-by":"crossref","first-page":"e621","DOI":"10.1111\/jdv.18780","article-title":"Successful treatment of PD-1 inhibitor-induced psoriasis with infliximab","volume":"37","author":"Hansen","year":"2023","journal-title":"J\u00a0Eur Acad Dermatol Venereol"},{"issue":"2","key":"10.1016\/j.det.2024.02.012_bib67","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1097\/CMR.0000000000000875","article-title":"Pembrolizumab-induced plaque psoriasis successfully treated with risankizumab in a patient with stage IV cutaneous melanoma","volume":"33","author":"Gargiulo","year":"2023","journal-title":"Melanoma Res"},{"issue":"3","key":"10.1016\/j.det.2024.02.012_bib68","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1093\/ced\/llac095","article-title":"Checkpoint inhibitor therapy and psoriasis: a case series","volume":"48","author":"Hussain","year":"2023","journal-title":"Clin Exp Dermatol"},{"issue":"1","key":"10.1016\/j.det.2024.02.012_bib69","doi-asserted-by":"crossref","DOI":"10.5070\/D329160215","article-title":"Atezolizumab-induced psoriasiform drug eruption successfully treated with ixekizumab: a case report and literature review","volume":"29","author":"Gleason","year":"2023","journal-title":"Dermatol Online J"},{"issue":"3","key":"10.1016\/j.det.2024.02.012_bib70","doi-asserted-by":"crossref","first-page":"e13363","DOI":"10.1111\/dth.13363","article-title":"Severe de-novo palmoplantar and nail psoriasis complicating Nivolumab treatment for metastatic melanoma","volume":"33","author":"Di Altobrando","year":"2020","journal-title":"Dermatol Ther"},{"issue":"2","key":"10.1016\/j.det.2024.02.012_bib71","doi-asserted-by":"crossref","first-page":"261","DOI":"10.4103\/idoj.IDOJ_47_19","article-title":"Nivolumab (PD-1 Inhibitor) Induced Exacerbation of Psoriasis","volume":"11","author":"George","year":"2020","journal-title":"Indian Dermatol Online J"},{"issue":"8","key":"10.1016\/j.det.2024.02.012_bib72","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1007\/s00105-017-4109-y","article-title":"[Initially undetected de novo psoriasis triggered by nivolumab for metastatic base of the tongue carcinoma]","volume":"69","author":"Troyanova-Slavkova","year":"2018","journal-title":"Hautarzt"},{"issue":"4","key":"10.1016\/j.det.2024.02.012_bib73","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1016\/j.jdcr.2017.11.014","article-title":"Psoriasiform eruption on the face and extremities associated with nivolumab therapy","volume":"4","author":"Om","year":"2018","journal-title":"JAAD Case Rep"},{"issue":"1","key":"10.1016\/j.det.2024.02.012_bib74","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1111\/1346-8138.13450","article-title":"Case of de novo psoriasis possibly triggered by nivolumab","volume":"44","author":"Murata","year":"2017","journal-title":"J\u00a0Dermatol"},{"issue":"9","key":"10.1016\/j.det.2024.02.012_bib75","first-page":"787","article-title":"[Psoriasis and Psoriatic Arthritis Induced by Nivolumab in a Patient with Advanced Non-Small-Cell Lung Cancer]","volume":"44","author":"Sugiura","year":"2017","journal-title":"Gan To Kagaku Ryoho"},{"issue":"8","key":"10.1016\/j.det.2024.02.012_bib76","doi-asserted-by":"crossref","DOI":"10.5070\/D3238036018","article-title":"A case of de novo palmoplantar psoriasis with psoriatic arthritis and autoimmune hypothyroidism after receiving nivolumab therapy","volume":"23","author":"Elosua-Gonz\u00e1lez","year":"2017","journal-title":"Dermatol Online J"},{"issue":"2","key":"10.1016\/j.det.2024.02.012_bib77","doi-asserted-by":"crossref","first-page":"95","DOI":"10.2177\/jsci.40.95","article-title":"Varied immuno-related adverse events induced by immune-check point inhibitors - Nivolumab-associated psoriasiform dermatitis related with increased serum level of interleukin-6","volume":"40","author":"Okiyama","year":"2017","journal-title":"Nihon Rinsho Meneki Gakkai Kaishi"},{"issue":"9","key":"10.1016\/j.det.2024.02.012_bib78","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.1111\/1346-8138.15371","article-title":"Durvalumab-induced de novo annular psoriasiform drug eruption successfully treated with a combination of narrowband ultraviolet B phototherapy and topical treatment","volume":"47","author":"Lin","year":"2020","journal-title":"J\u00a0Dermatol"},{"issue":"10","key":"10.1016\/j.det.2024.02.012_bib79","doi-asserted-by":"crossref","first-page":"1343","DOI":"10.1111\/1346-8138.16832","article-title":"Simultaneous development of generalized pustular psoriasis and pemphigoid with multiple autoantibodies in a complete responder of pembrolizumab for lung cancer","volume":"50","author":"Kochi","year":"2023","journal-title":"J\u00a0Dermatol"},{"issue":"8","key":"10.1016\/j.det.2024.02.012_bib80","doi-asserted-by":"crossref","first-page":"2197","DOI":"10.1007\/s00262-021-02851-5","article-title":"Preexisting autoimmune disease and immune-related adverse events associated with anti-PD-1 cancer immunotherapy: a national case series from the Canadian Research Group of Rheumatology in Immuno-Oncology","volume":"70","author":"Hoa","year":"2021","journal-title":"Cancer Immunol Immunother"},{"issue":"1","key":"10.1016\/j.det.2024.02.012_bib81","doi-asserted-by":"crossref","first-page":"e14653","DOI":"10.1111\/dth.14653","article-title":"Successful treatment with apremilast of severe psoriasis exacerbation during nivolumab therapy for metastatic melanoma","volume":"34","author":"Foti","year":"2021","journal-title":"Dermatol Ther"},{"issue":"6","key":"10.1016\/j.det.2024.02.012_bib82","doi-asserted-by":"crossref","first-page":"e829","DOI":"10.1016\/j.cllc.2021.04.002","article-title":"Palmoplantar Pustulosis Caused by Immune-Checkpoint Inhibitors","volume":"22","author":"Furuta","year":"2021","journal-title":"Clin Lung Cancer"},{"key":"10.1016\/j.det.2024.02.012_bib83","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.ejca.2016.12.038","article-title":"Programmed cell death protein-1 (PD-1) inhibitor therapy in patients with advanced melanoma and preexisting autoimmunity or ipilimumab-triggered autoimmunity","volume":"75","author":"Gutzmer","year":"2017","journal-title":"Eur J Cancer"},{"issue":"5","key":"10.1016\/j.det.2024.02.012_bib84","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1007\/s00262-018-2134-z","article-title":"Ipilimumab in metastatic melanoma patients with pre-existing autoimmune disorders","volume":"67","author":"Kahler","year":"2018","journal-title":"Cancer Immunol Immunother"},{"key":"10.1016\/j.det.2024.02.012_bib85","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1016\/j.ejca.2020.07.023","article-title":"Safety and efficacy of atezolizumab in patients with autoimmune disease: Subgroup analysis of the SAUL study in locally advanced\/metastatic urinary tract carcinoma","volume":"138","author":"Loriot","year":"2020","journal-title":"Eur J Cancer"},{"issue":"1","key":"10.1016\/j.det.2024.02.012_bib86","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s00403-020-02094-x","article-title":"Vitamin D, autoimmunity and immune-related adverse events of immune checkpoint inhibitors","volume":"313","author":"Sun","year":"2021","journal-title":"Arch Dermatol Res"},{"issue":"6","key":"10.1016\/j.det.2024.02.012_bib87","first-page":"e15703","article-title":"A\u00a0Case of De Novo Psoriasis Secondary to Nivolumab in a Patient With Metastatic Renal Cell Carcinoma","volume":"13","author":"Mullangi","year":"2021","journal-title":"Cureus"},{"issue":"8","key":"10.1016\/j.det.2024.02.012_bib88","first-page":"911","article-title":"Nivolumab Induced Psoriasis Successfully Treated With Acitretin","volume":"20","author":"Killion","year":"2021","journal-title":"J\u00a0Drugs Dermatol"},{"key":"10.1016\/j.det.2024.02.012_bib89","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1016\/j.ijscr.2017.04.029","article-title":"Apocrine sweat gland adenocarcinoma: A rare case report and review","volume":"36","author":"Gatti","year":"2017","journal-title":"Int J Surg Case Rep"},{"key":"10.1016\/j.det.2024.02.012_bib90","article-title":"The use of interleukin-23 inhibitors to treat immune-related psoriasis induced by immune checkpoint inhibitors and in patients with active cancer: A case series and review of the literature","volume":"11","author":"Fournier","year":"2023","journal-title":"SAGE Open Med Case Rep"},{"key":"10.1016\/j.det.2024.02.012_bib91","first-page":"6215958","article-title":"De Novo Psoriasis Vulgaris Diagnosed after Nivolumab Treatment for Refractory Hodgkin's Lymphoma, Completely Resolved after Autologous Hematopoietic Stem Cell Transplantation","volume":"2018","author":"Kaloyannidis","year":"2018","journal-title":"Case Rep Hematol"},{"issue":"4","key":"10.1016\/j.det.2024.02.012_bib92","doi-asserted-by":"crossref","first-page":"LMT51","DOI":"10.2217\/lmt-2021-0003","article-title":"Use of immune checkpoint inhibitors in patients with solid tumors and pre-existing autoimmune or inflammatory disease: real-world data","volume":"10","author":"Calvo","year":"2021","journal-title":"Lung Cancer Manag"},{"issue":"19","key":"10.1016\/j.det.2024.02.012_bib93","doi-asserted-by":"crossref","first-page":"1905","DOI":"10.1200\/JCO.2017.77.0305","article-title":"Safety of Programmed Death-1 Pathway Inhibitors Among Patients With Non-Small-Cell Lung Cancer and Preexisting Autoimmune Disorders","volume":"36","author":"Leonardi","year":"2018","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.det.2024.02.012_bib94","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.ejca.2017.12.008","article-title":"Safety and efficacy of anti-programmed death 1 antibodies in patients with cancer and pre-existing autoimmune or inflammatory disease","volume":"91","author":"Danlos","year":"2018","journal-title":"Eur J Cancer"},{"issue":"2","key":"10.1016\/j.det.2024.02.012_bib95","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1093\/annonc\/mdw443","article-title":"Anti-PD-1 therapy in patients with advanced melanoma and preexisting autoimmune disorders or major toxicity with ipilimumab","volume":"28","author":"Menzies","year":"2017","journal-title":"Ann Oncol"},{"issue":"2","key":"10.1016\/j.det.2024.02.012_bib96","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1001\/jamaoncol.2015.4368","article-title":"Ipilimumab Therapy in Patients With Advanced Melanoma and Preexisting Autoimmune Disorders","volume":"2","author":"Johnson","year":"2016","journal-title":"JAMA Oncol"},{"issue":"6","key":"10.1016\/j.det.2024.02.012_bib97","doi-asserted-by":"crossref","first-page":"871","DOI":"10.2169\/internalmedicine.3694-19","article-title":"Systemic Psoriasiform Dermatitis Appeared after the Administration of Pembrolizumab","volume":"59","author":"Suzuki","year":"2020","journal-title":"Intern Med"},{"issue":"4","key":"10.1016\/j.det.2024.02.012_bib98","article-title":"Pembrolizumab Therapy Triggering an Exacerbation of Preexisting Autoimmune Disease: A Report of 2 Patient Cases","volume":"4","author":"Phadke","year":"2016","journal-title":"J\u00a0Investig Med High Impact Case Rep"},{"issue":"9","key":"10.1016\/j.det.2024.02.012_bib99","doi-asserted-by":"crossref","first-page":"e331","DOI":"10.1111\/ijd.14876","article-title":"Inverse psoriasis in patient treated with atezolizumab","volume":"59","author":"Corneli","year":"2020","journal-title":"Int J Dermatol"},{"key":"10.1016\/j.det.2024.02.012_bib100","doi-asserted-by":"crossref","DOI":"10.1177\/1758834017751634","article-title":"Diverse cutaneous adverse eruptions caused by anti-programmed cell death-1 (PD-1) and anti-programmed cell death ligand-1 (PD-L1) immunotherapies: clinical features and management","volume":"10","author":"Shen","year":"2018","journal-title":"Ther Adv Med Oncol"},{"key":"10.1016\/j.det.2024.02.012_bib101","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1016\/j.ejca.2016.02.025","article-title":"Cutaneous, gastrointestinal, hepatic, endocrine, and renal side-effects of anti-PD-1 therapy","volume":"60","author":"Hofmann","year":"2016","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.det.2024.02.012_bib102","first-page":"182","article-title":"Psoriatic arthritis due to nivolumab administration a case report and review of the literature","volume":"23","author":"Sapalidis","year":"2018","journal-title":"Respir Med Case Rep"},{"issue":"2","key":"10.1016\/j.det.2024.02.012_bib103","first-page":"186","article-title":"Mycosis fungoides, Psoriasis und PD-1-Inhibitoren - neuer Aspekt einer bekannten Assoziation","volume":"17","author":"Geller","year":"2019","journal-title":"J\u00a0Dtsch Dermatol Ges"},{"issue":"6","key":"10.1016\/j.det.2024.02.012_bib104","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1007\/s40257-018-0376-3","article-title":"Retrospective Chart Review of Cutaneous Adverse Events Associated with Tremelimumab in 17 Patients","volume":"19","author":"Welborn","year":"2018","journal-title":"Am J Clin Dermatol"},{"key":"10.1016\/j.det.2024.02.012_bib105","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1016\/j.lungcan.2020.06.012","article-title":"Pembrolizumab-induced linear psoriasis","volume":"146","author":"Huang","year":"2020","journal-title":"Lung Cancer"},{"issue":"8","key":"10.1016\/j.det.2024.02.012_bib106","doi-asserted-by":"crossref","first-page":"e151","DOI":"10.1111\/ijd.14457","article-title":"Follicular psoriasis induced by pembrolizumab in a patient with advanced non-small-cell lung cancer","volume":"58","author":"Scarfi","year":"2019","journal-title":"Int J Dermatol"},{"issue":"1","key":"10.1016\/j.det.2024.02.012_bib107","doi-asserted-by":"crossref","first-page":"e14651","DOI":"10.1111\/dth.14651","article-title":"New-onset psoriasiform dermatitis in a patient treated with nivolumab for sarcomatoid carcinoma of the head and neck","volume":"34","author":"Seyit","year":"2021","journal-title":"Dermatol Ther"},{"issue":"5","key":"10.1016\/j.det.2024.02.012_bib108","first-page":"202","article-title":"Severe Psoriasis Flare After Anti-Programmed Death Ligand 1 (PD-L1) Therapy for Metastatic Non-Small Cell Lung Cancer (NSCLC)","volume":"39","author":"Chia","year":"2016","journal-title":"J\u00a0Immunother"},{"issue":"12","key":"10.1016\/j.det.2024.02.012_bib109","doi-asserted-by":"crossref","first-page":"e466","DOI":"10.1111\/1346-8138.15040","article-title":"Psoriatic arthritis induced by anti-programmed death 1 antibody pembrolizumab","volume":"46","author":"Hara","year":"2019","journal-title":"J\u00a0Dermatol"},{"issue":"8","key":"10.1016\/j.det.2024.02.012_bib110","first-page":"e28010","article-title":"Immune Checkpoint Inhibitor-Induced Psoriasiform, Spongiotic, and Lichenoid Dermatitis: A Novel Clinicopathological Pattern","volume":"14","author":"Kost","year":"2022","journal-title":"Cureus"},{"issue":"11","key":"10.1016\/j.det.2024.02.012_bib111","doi-asserted-by":"crossref","first-page":"1206","DOI":"10.1001\/jamadermatol.2015.1916","article-title":"Pembrolizumab Cutaneous Adverse Events and Their Association With Disease Progression","volume":"151","author":"Sanlorenzo","year":"2015","journal-title":"JAMA Dermatol"},{"issue":"4","key":"10.1016\/j.det.2024.02.012_bib112","doi-asserted-by":"crossref","first-page":"367","DOI":"10.31138\/mjr.32.4.367","article-title":"Polyarthritis and Psoriasiform Skin Lesions following Pembrolizumab Therapy","volume":"32","author":"Koulouri","year":"2021","journal-title":"Mediterr J Rheumatol"},{"issue":"5","key":"10.1016\/j.det.2024.02.012_bib113","doi-asserted-by":"crossref","first-page":"e162","DOI":"10.1097\/RHU.0000000000001301","article-title":"Nivolumab-Induced Psoriatic Arthritis in a Patient With Advanced Small Cell Lung Cancer","volume":"27","author":"Jatwani","year":"2021","journal-title":"J\u00a0Clin Rheumatol"},{"issue":"4","key":"10.1016\/j.det.2024.02.012_bib114","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1016\/j.ad.2020.05.025","article-title":"Psoriasis and Anti-PD-1 and Anti-PD-L1 Immunotherapy: Three Cases, a Review of the Literature, and a Proposed Management Algorithm","volume":"113","author":"Sanchez-Martinez","year":"2022","journal-title":"Actas Dermosifiliogr"},{"key":"10.1016\/j.det.2024.02.012_bib115","doi-asserted-by":"crossref","first-page":"579445","DOI":"10.3389\/fonc.2020.579445","article-title":"Pembrolizumab-Induced Psoriasis in Metastatic Melanoma: Activity and Safety of Apremilast, a Case Report","volume":"10","author":"Siciliano","year":"2020","journal-title":"Front Oncol"},{"issue":"5","key":"10.1016\/j.det.2024.02.012_bib116","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1016\/j.jdcr.2020.03.001","article-title":"Successful treatment of HIV-negative Kaposi sarcoma with ipilimumab and nivolumab and concurrent management of baseline psoriasis and bullous pemphigoid","volume":"6","author":"Tabata","year":"2020","journal-title":"JAAD Case Rep"},{"issue":"5","key":"10.1016\/j.det.2024.02.012_bib117","doi-asserted-by":"crossref","first-page":"3776","DOI":"10.21037\/tcr.2020.03.57","article-title":"Atezolizumab-induced psoriasis in a patient with metastatic lung cancer-a case report","volume":"9","author":"Mao","year":"2020","journal-title":"Transl Cancer Res"},{"issue":"5","key":"10.1016\/j.det.2024.02.012_bib118","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1001\/jamadermatol.2015.5210","article-title":"Inverse Psoriasiform Eruption During Pembrolizumab Therapy for Metastatic Melanoma","volume":"152","author":"Totonchy","year":"2016","journal-title":"JAMA Dermatol"},{"key":"10.1016\/j.det.2024.02.012_bib119","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.ejca.2017.05.032","article-title":"Prevalence of immune-related systemic adverse events in patients treated with anti-Programmed cell Death 1\/anti-Programmed cell Death-Ligand 1 agents: A single-centre pharmacovigilance database analysis","volume":"82","author":"Le Burel","year":"2017","journal-title":"Eur J Cancer"},{"issue":"5","key":"10.1016\/j.det.2024.02.012_bib120","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1016\/j.ad.2018.02.029","article-title":"Plaque Psoriasis Flare and Peripheral Edema in a Patient Treated With Atezolizumab","volume":"110","author":"Santos-Juanes","year":"2019","journal-title":"Actas Dermosifiliogr (Engl Ed)."},{"issue":"5","key":"10.1016\/j.det.2024.02.012_bib121","doi-asserted-by":"crossref","first-page":"580","DOI":"10.4103\/ijdvl.IJDVL_1067_19","article-title":"Rupioid psoriasis induced by pembrolizumab","volume":"86","author":"Marti-Marti","year":"2020","journal-title":"Indian J Dermatol Venereol Leprol"},{"issue":"10","key":"10.1016\/j.det.2024.02.012_bib122","doi-asserted-by":"crossref","first-page":"1381","DOI":"10.1097\/PAS.0000000000000900","article-title":"Cutaneous Eruptions in Patients Receiving Immune Checkpoint Blockade: Clinicopathologic Analysis of the Nonlichenoid Histologic Pattern","volume":"41","author":"Kaunitz","year":"2017","journal-title":"Am J Surg Pathol"},{"issue":"1","key":"10.1016\/j.det.2024.02.012_bib123","doi-asserted-by":"crossref","first-page":"88","DOI":"10.4103\/ijd.IJD_46_17","article-title":"Anti-Programmed Cell Death-1-Induced Plaque and Guttate Psoriasis","volume":"63","author":"Yamamoto","year":"2018","journal-title":"Indian J Dermatol"},{"key":"10.1016\/j.det.2024.02.012_bib124","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1002\/cia2.12087","article-title":"A\u00a0case of de novo psoriasis induced by atezolizumab in a patient with advanced lung cancer","volume":"2","author":"Iijima","year":"2019","journal-title":"J\u00a0Cutan Immunol Allergy"},{"issue":"2","key":"10.1016\/j.det.2024.02.012_bib125","doi-asserted-by":"crossref","first-page":"106","DOI":"10.12788\/jcso.0262","article-title":"Palmoplantar exacerbation of psoriasis after nivolumab for lung cancer","volume":"15","author":"Liebman","year":"2017","journal-title":"Journal of Community and Supportive Oncology"},{"key":"10.1016\/j.det.2024.02.012_bib126","doi-asserted-by":"crossref","first-page":"157","DOI":"10.4103\/ds.ds_45_18","article-title":"Cyclosporine but not acitretin for psoriasis exacerbation and general Myalgia induced by Pembrolizumab in a patient with advanced esophageal cancer","volume":"37","author":"Tseng","year":"2019","journal-title":"Dermatologica Sinica"}],"container-title":["Dermatologic Clinics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S073386352400024X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S073386352400024X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,5,23]],"date-time":"2024-05-23T21:40:04Z","timestamp":1716500404000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S073386352400024X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7]]},"references-count":126,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2024,7]]}},"alternative-id":["S073386352400024X"],"URL":"https:\/\/doi.org\/10.1016\/j.det.2024.02.012","relation":{},"ISSN":["0733-8635"],"issn-type":[{"value":"0733-8635","type":"print"}],"subject":[],"published":{"date-parts":[[2024,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Immune Checkpoint Inhibitor-Induced Psoriasis","name":"articletitle","label":"Article Title"},{"value":"Dermatologic Clinics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.det.2024.02.012","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}